Activation of the PI3K/Akt pathway appears to favor development of mixed lineage diseases that begin as MPNs, but rapidly progress to more aggressive diseases, namely T cell lymphomas and T-ALLs, while only a small percentage develop AML [20], [21], [22], [23]. Here, AKT1 is linked to T-cell non-Hodgkin lymphoma.